A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers.
- Author:
Ning LIAO
1
;
Guo-chun ZHANG
;
Xue-rui LI
;
Meng YAO
;
Kun WANG
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal; administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; metabolism; Female; Humans; Neoadjuvant Therapy; methods; Randomized Controlled Trials as Topic; Receptor, ErbB-2; genetics; metabolism; Trastuzumab
- From: Journal of Southern Medical University 2009;29(5):943-945
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of neoadjuvant chemotherapy combined with trastuzumab for HER2 positive breast cancers.
METHODSPubMed online database, ASCO abstract database, SABCS abstract database, ESMO abstract database and CBMdisc database were searched for literatures related to trastuzumab in neoadjuvant chemotherapy for breast cancers. A meta-analysis was performed for retrieved literatures meeting the inclusion criteria.
RESULTSThree clinical trials were included. Meta-analysis showed that compared to chemotherapy only, regimens combined with trastuzumab could significantly improved the pCR rate of HER2-positive breast cancers (RR=1.65, 95% CI 1.28-2.13, P<0.0001) without increasing the frequencies of cardiac toxicity (RR=1.16, 95% CI 0.82-1.64, P=0.41).
CONCLUSIONIn neoadjuvant chemotherapy for HER2-positive breast cancers, chemotherapy combined with trastuzumab is superior to exclusive chemotherapy.
